80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]章杰城,林宜淋,賴傳進(jìn),等.米拉貝隆聯(lián)合索利那新防治前列腺電切術(shù)后導(dǎo)尿管相關(guān)膀胱刺激癥的療效分析[J].福建醫(yī)藥雜志,2024,46(01):12-17.[doi:10.20148/j.fmj.2024.01.004]
　ZHANG Jiecheng,LIN Yilin,LAI Chuanjin,et al.Efficacy and safety of mirabegron combined with solifenacin for catheter related bladder discomfort in patients undergoing transurethral resection of the prostate：A prospective case-control study[J].FUJIAN MEDICAL JOURNAL,2024,46(01):12-17.[doi:10.20148/j.fmj.2024.01.004]
點(diǎn)擊復(fù)制

米拉貝隆聯(lián)合索利那新防治前列腺電切術(shù)后導(dǎo)尿管相關(guān)膀胱刺激癥的療效分析()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期數(shù):
2024年01期
頁碼:
12-17
欄目:
臨床研究
出版日期:
2024-02-15

文章信息/Info

Title:
Efficacy and safety of mirabegron combined with solifenacin for catheter related bladder discomfort in patients undergoing transurethral resection of the prostate：A prospective case-control study
文章編號(hào):
1002-2600（2024）01-0012-06
作者:
章杰城; 林宜淋; 賴傳進(jìn); 童明燁; 呂金星; 張金墩; 郭國(guó)建; 李松川; 蘇宏樹
福建省德化縣醫(yī)院泌尿外科，泉州 362500；Email：[email protected]
Author(s):
ZHANG Jiecheng;  LIN Yilin;  LAI Chuanjin;  TONG Mingye;  LV Jinxing;  ZHANG Jindun;  GUO Guojian;  LI Songchuan;  SU Hongshu
Department of Urology, Dehua County Hospital, Quanzhou, Fujian 362500, China
關(guān)鍵詞:
米拉貝隆; 索利那新; 前列腺電切; 導(dǎo)尿管相關(guān)膀胱刺激征; β3腎上腺受體激動(dòng)劑; 靜脈給藥量; M受體拮抗劑
Keywords:
mirabegron;  solifenacin;  transurethral resection of the prostate ;  catheter related bladder discomfort; β3 adrenoceptor agonist;  amount of intravenous fluids;  muscarinic receptor antagonists
分類號(hào):
R699.6
DOI:
10.20148/j.fmj.2024.01.004
文獻(xiàn)標(biāo)志碼:
A
摘要:
目的論證米拉貝隆聯(lián)合索利那新防治經(jīng)尿道前列腺電切術(shù)(TURP)術(shù)后導(dǎo)尿管相關(guān)膀胱刺激癥(CRBD)的有效性和安全性。方法將符合標(biāo)準(zhǔn)的108例接受TURP手術(shù)的前列腺增生患者隨機(jī)分為三組，每組36例；術(shù)前1天開始M+S組給予口服米拉貝隆50 mg/d聯(lián)合索利那新5 mg/d；S組服用單藥索利那新5 mg/d；C組僅接受TURP手術(shù)。對(duì)術(shù)后出現(xiàn)中度以上CRBD的患者進(jìn)行自制綜合量表評(píng)分，達(dá)到設(shè)定標(biāo)準(zhǔn)的予靜脈滴注間苯三酚處理。觀察各組術(shù)后第1、3、5天CRBD發(fā)生情況，術(shù)后5天內(nèi)靜脈給藥量，持續(xù)膀胱沖洗時(shí)間及藥物不良反應(yīng)。結(jié)果共有106例患者納入最終的分析，M+S組除了術(shù)后第1天在中度和重度CRBD的發(fā)生率上與S組相當(dāng)外，在其他時(shí)間節(jié)點(diǎn)的CRBD總發(fā)生率、中度和重度CRBD發(fā)生率及靜脈給藥量上均明顯優(yōu)于S組及C組（P＜0.05）；S組與C組相比在任何時(shí)間節(jié)點(diǎn)均沒有降低CRBD總發(fā)生率（P＞0.05），但在中度和重度CRBD的發(fā)生率及靜脈用藥量上優(yōu)于C組（P＜0.05）。3組術(shù)前及術(shù)后第1、3、5天的心率、收縮壓、舒張壓值均無統(tǒng)計(jì)學(xué)意義（P＞0.05）；M+S組和S組中新發(fā)口干、便秘的例數(shù)略多于C組，但是差異無統(tǒng)計(jì)學(xué)意義（P＞0.05）；M+S組額外報(bào)告1例新發(fā)皮疹。結(jié)論米拉貝隆聯(lián)合索利那新可降低TURP術(shù)后CRBD的發(fā)生率，減少患者靜脈解痙藥物的應(yīng)用，較單藥索利那新效果更優(yōu)且不增加藥物不良反應(yīng)。
Abstract:
ObjectiveTo investigate the safety and efficacy of mirabegron combined with solifenacin in the treatment of CRBD after TURP. MethodsA total of 108 patients with BPH who underwent TURP were randomly divided into three groups, 36 cases in each group. Patients in M+S group were given oral mirabegron 50 mg/d combined with solifenacin 5 mg/d from one day before surgery; S group was given solifenacin 5 mg/d; C group received surgical treatment only. Patients with more than moderate degree of CRBD after operation were scored, and those who met the indications were given intravenous spasmodic and analgesic treatment. The occurrence of CRBD in each group at the 1st, 3rd and 5th day after surgery and the amount of intravenous fluids within the 5th day after surgery were recorded, the time of continuous catheter washout and adverse drug reactions were also recorded. ResultsA total of 106 patients were included in the final analysis. On postoperative day 1, the probability of more than moderate CRBD was not significantly different between the M+S and S groups（P＞0.05）, in addition, the incidence of overall CRBD, the incidence of more than moderate CRBD, and the amount of intravenous fluids in the M+S group were significantly less than those in the S and C groups at any time point(P<0.05). Compared with C group, S group did not reduce the overall incidence of CRBD(P>0.05), but the incidence of CRBD above moderate degree and the amount of intravenous infusion were better than those in C group(P<0.05). There was no difference in heart rate, systolic blood pressure and diastolic blood pressure between the three groups before surgery and 1, 3 and 5 days after surgery(P>0.05). There was no difference in the incidence of dry mouth, constipation, too(P>0.05). One additional case of rash was reported in the M+S group. ConclusionMirabegron combined with solifenacin can reduce the incidence of CRBD after TURP, reduce the intravenous use of spasmolytics， and has a more significant effect than solifenacin alone without increasing adverse drug reactions.

參考文獻(xiàn)/References:

[1] CHUNG J M,HA H K,KIM D H,et al.Evaluation of the efficacy of solifenacin for preventing catheter-related bladder discomfort after transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer：A prospective,randomized,multicenter study[J].Clin Genitourin Cancer,2017,15(1):157-162.
[2] ZHANG Z,CAO Z,XU C,et al.Solifenacin is able to improve the irritative symptoms after transurethral resection of bladder tumors[J].Urology,2014,84(1):117-121.
[3] WANG J P,ZHOU Z B,CUI Y S,et al.Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder[J].Neurourol Urodyn,2019,38(1):22-30.
[4] GRATZKE C,VAN MAANEN R,CHAPPLE C,et al.Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder：A randomised,multicentre phase 3 study(SYNERGY Ⅱ)[J].Eur Urol,2018,74(4):501-509.
[5] KELLEHER C,HAKIMI Z,ZUR R,et al. Efficacy and tolerability of mirabegron compared with antimuscarinic mono-therapy or combination therapies for overactive bladder：A systematic review and network Meta-analysis[J].Eur Urol,2018,74(3):324-333.
[6] YAMANISHI T,CHAPPLE C R,CHESS-WILLIAMS R.
Which muscarinic receptor is important in the bladder?[J].World J Urol,2001,19(5):299-306.
[7] REN J,YU T,TIAN Y,et al.Comparative effectiveness of interventions for managing urological postoperative catheter-related bladder discomfort：a systematic review and network meta-analysis[J].BMC Urol,2023,23(1):29.
[8] LI S,LI P,WANG R,et al.Different interventions for preventing postoperative catheter-related bladder discomfort：a systematic review and meta-analysis[J].Eur J Clin Pharmacol,2022,78(6):897-906.
[9] JANG E B,HONG S H,KIM K S,et al.Catheter-related bladder discomfort：how can we manage it?[J].Int Neurourol J,2020,24(4):324-331.
[10] AGARWAL A,DHIRAAJ S,SINGHAL V,et al.Compa-rison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort：a prospective,randomized,placebo-controlled,double-blind study[J].Br J Anaesth,2006,96(3):377-380.
[11] PENG X F,LV X G,XIE H,et al.Effectiveness of solifenacin for managing of bladder spasms in patients with urethroplasty[J].Am J Mens Health,2017,11(5):1580-1587.
[12] IN C B,LEE S J,SUNG T Y,et al.Effects of chlorpheniramine maleate on catheter-related bladder discomfort in patients undergoing ureteroscopic stone removal：a randomized double-blind study[J].Int J Med Sci,2021,18(4):1075-1081.
[13] SRIVASTAVA V K,AGRAWAL S,KADIYALA V N,et al.The efficacy of pregabalin for prevention of catheter-related bladder discomfort：a prospective,randomized,placebo-controlled double-blind study[J].J Anesth,2015,29(2):212-216.
[14] CHEON Y W,KIM S H,PAEK J H,et al.Effects of nefopam on catheter-related bladder discomfort in patients undergoing ureteroscopic litholapaxy[J].Korean J Anesthesiol,2018,71(3):201-206.
[15] LI S Y,LI H,NI J,et al.Comparison of intravenous lidocaine and dexmedetomidine infusion for prevention of postoperative catheter-related bladder discomfort：a randomized controlled trial[J].BMC Anesthesiol,2019,19(1):37.
[16] KENNELLY M J,RHODES T,GIRMAN C J,et al.efficacy of vibegron and mirabegron for overactive bladder：a systematic literature review and indirect treatment comparison [J].Adv Ther,2021,38(11):5452-5464.
[17] DEEKS E D.MIRABEGRON：a review in overactive bladder syndrome[J].Drugs,2018,78(8):833-844.
[18] FAN B,SHEN J,WU L,et al.Study of mirabegron and solifenacin in the improvement of catheter-related bladder discomfort in patients undergoing transurethral resection：a case-control study[J].Medicine(Baltimore),2022,101(48):e32052.
[19] 陳鐵定,王蔭槐,楊羅艷,等.間苯三酚預(yù)防前列腺電切術(shù)后膀胱痙攣的療效分析[J].中華男科學(xué)雜志,2010,16(11):1004-1006.
[20] MUELLER E R,VAN MAANEN R,CHAPPLE C,et al.Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin：a prespecified analysis from the randomized,phase Ⅲ SYNERGY Ⅱ study[J].Neurourol Urodyn,2019,38(2):779-792.

備注/Memo

備注/Memo:
基金項(xiàng)目：福建省泉州市科技計(jì)劃項(xiàng)目醫(yī)學(xué)與臨床科研項(xiàng)目（NO.2020N087s）
通信作者：蘇宏樹，主任醫(yī)師，Email：[email protected]
更新日期/Last Update: 2024-02-15